国际生物制品学杂志
國際生物製品學雜誌
국제생물제품학잡지
INTERNATIONAL JOURNAL OF BIOLOGICALS
2011年
3期
121-125
,共5页
黄杨%王凤%王倩%陈家丽%仇超%徐建青
黃楊%王鳳%王倩%陳傢麗%仇超%徐建青
황양%왕봉%왕천%진가려%구초%서건청
流感病毒A型,H1N1亚型%疫苗,DNA%血凝素类%免疫原性%中和抗体
流感病毒A型,H1N1亞型%疫苗,DNA%血凝素類%免疫原性%中和抗體
류감병독A형,H1N1아형%역묘,DNA%혈응소류%면역원성%중화항체
Influenza A virus,H1N1 subtype%Vaccines,DNA%Hemagglutinins%Immunogenicity%Neutralization antibody
目的 构建表达甲型H1N1流感病毒血凝素(hemagglutinin,HA)抗原的DNA疫苗,并在小鼠中测试其免疫原性.方法 运用人密码子优化技术合成甲型H1N1流感病毒HA序列,并转移至DNA疫苗载体,用Western blotting检测其表达效率.采用单纯随机抽样方法把BALB/c小鼠分成DNA疫苗组和对照组.用DNA疫苗免疫疫苗组小鼠,免疫后取小鼠血清和脾细胞,分别用ELISA方法和酶联免疫斑点试验(ELISPOT)方法检测血清中的特异性抗体应答和脾细胞中的特异性T细胞应答,最后用血凝抑制(hemagglutination inhibition,HI)试验和假病毒中和试验分别检测血清中的HI抗体和中和抗体应答.采用t检验作两组之间比较.结果 所构建的DNA疫苗能够高效表达HA蛋白.免疫小鼠后能有效诱导T细胞免疫应答[429 0±113 4斑点形成细胞(spot-forming cell,SFC)/10°脾细胞],血清结合抗体滴度为16127 0±2698.0,HI抗体滴度为100.8±16 9,所有数据均显著高于载体对照(分别为t=3.863,P=0.0042;t=5.734,P=0.0002;t=6.018,P=0.0001).DNA疫苗能活化产生高水平的针对同源H1N1毒株的中和抗体,但不能活化产生针对异源H1N1毒株的中和抗体.结论 本研究构建的DNA疫苗有较好的免疫原性,并能诱导一定水平的保护性抗体产生.
目的 構建錶達甲型H1N1流感病毒血凝素(hemagglutinin,HA)抗原的DNA疫苗,併在小鼠中測試其免疫原性.方法 運用人密碼子優化技術閤成甲型H1N1流感病毒HA序列,併轉移至DNA疫苗載體,用Western blotting檢測其錶達效率.採用單純隨機抽樣方法把BALB/c小鼠分成DNA疫苗組和對照組.用DNA疫苗免疫疫苗組小鼠,免疫後取小鼠血清和脾細胞,分彆用ELISA方法和酶聯免疫斑點試驗(ELISPOT)方法檢測血清中的特異性抗體應答和脾細胞中的特異性T細胞應答,最後用血凝抑製(hemagglutination inhibition,HI)試驗和假病毒中和試驗分彆檢測血清中的HI抗體和中和抗體應答.採用t檢驗作兩組之間比較.結果 所構建的DNA疫苗能夠高效錶達HA蛋白.免疫小鼠後能有效誘導T細胞免疫應答[429 0±113 4斑點形成細胞(spot-forming cell,SFC)/10°脾細胞],血清結閤抗體滴度為16127 0±2698.0,HI抗體滴度為100.8±16 9,所有數據均顯著高于載體對照(分彆為t=3.863,P=0.0042;t=5.734,P=0.0002;t=6.018,P=0.0001).DNA疫苗能活化產生高水平的針對同源H1N1毒株的中和抗體,但不能活化產生針對異源H1N1毒株的中和抗體.結論 本研究構建的DNA疫苗有較好的免疫原性,併能誘導一定水平的保護性抗體產生.
목적 구건표체갑형H1N1류감병독혈응소(hemagglutinin,HA)항원적DNA역묘,병재소서중측시기면역원성.방법 운용인밀마자우화기술합성갑형H1N1류감병독HA서렬,병전이지DNA역묘재체,용Western blotting검측기표체효솔.채용단순수궤추양방법파BALB/c소서분성DNA역묘조화대조조.용DNA역묘면역역묘조소서,면역후취소서혈청화비세포,분별용ELISA방법화매련면역반점시험(ELISPOT)방법검측혈청중적특이성항체응답화비세포중적특이성T세포응답,최후용혈응억제(hemagglutination inhibition,HI)시험화가병독중화시험분별검측혈청중적HI항체화중화항체응답.채용t검험작량조지간비교.결과 소구건적DNA역묘능구고효표체HA단백.면역소서후능유효유도T세포면역응답[429 0±113 4반점형성세포(spot-forming cell,SFC)/10°비세포],혈청결합항체적도위16127 0±2698.0,HI항체적도위100.8±16 9,소유수거균현저고우재체대조(분별위t=3.863,P=0.0042;t=5.734,P=0.0002;t=6.018,P=0.0001).DNA역묘능활화산생고수평적침대동원H1N1독주적중화항체,단불능활화산생침대이원H1N1독주적중화항체.결론 본연구구건적DNA역묘유교호적면역원성,병능유도일정수평적보호성항체산생.
Objective To construct DNA vaccine expressing influenza A ( H1N1) virus hemagglutinin (HA) antigen, and to evaluate its immunogenicity in mice. Methods The condon-optimized influenza A ( H1N1) virus HA sequence was synthesized and transferred to DNA vaccine vector, and its expression efficacy was proved by Western blotting in vitro. BALB/c mice were divided into DNA vaccine group and control group by simple random sampling for the evaluation of DNA vaccine immunogenicity. After the final inoculation, spleens and sera were collected from the immunized mice. HA-specific antibody responses in sera and T cell responses in splenocytes were quantified by ELISA and enzyme-linked immunospot assay ( ELISPOT) , respectively. In addition, hemagglutination inhibition (HI) and neutralizing antibodies were determined by HI assay and pseudovirus based neutralization assay, respectively. The t test was adopted in the comparison between the two groups. Results The constructed DNA vaccine could efficiently express HA protein in vitro. The inoculation of DNA vaccine in mice was capable of inducing vigorous T cell responses [429. 0 ± 113. 4 spot-forming cell (SFC)/106 splenocytes], the binding antibody liters in sera reached 16127.0 ±2698.0, and HI antibody tilers were 100. 8 ± 16. 9. All these data were significantly higher than those in vector control group (t=3.863, P=0.0042; t=5.734, P=0.0002; t =6. 018, P=0.0001, respectively). Furthermore,DNA vaccine could elicit high levels of neutralizing antibodies against homogenous H1N1 virus.but not against H1N1 heterogenous ones.Conclusions The constructed DNA vaccine is highly immunogenic and could induce high level of protective immunity.